


PHARMACEUTICAL 2021



Corvus Pharmaceuticals Inc. Rank 47 of 409





PHARMACEUTICAL 2021



Corvus Pharmaceuticals Inc. Rank 47 of 409

The relative strengths and weaknesses of Corvus Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corvus Pharmaceuticals Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 319% points. The greatest weakness of Corvus Pharmaceuticals Inc. is the variable Revenues, reducing the Economic Capital Ratio by 105% points.

The company's Economic Capital Ratio, given in the ranking table, is 111%, being 466% points above the market average of -355%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 45,336 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 12,149 |
| Liabilities, Non-Current | 1,232 |
| Other Assets | 39,287 |
| Other Compr. Net Income | -25 |
| Other Expenses | 0 |
| Other Liabilities | 0 |
| Other Net Income | 37,765 |
| Property and Equipment | 906 |
| Research and Development | 31,830 |
| Revenues | 0 |
| Selling, General and Administrative Expense | 11,930 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 85,529 |
| Liabilities | 13,381 |
| Expenses | 43,760 |
| Stockholders Equity | 72,148 |
| Net Income | -5,995 |
| Comprehensive Net Income | -6,008 |
| Economic Capital Ratio | 111% |